Sarpogrelate,a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European study

Abstract

This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT_2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent claudication. Following a single-blind placebo run-in period of 6 weeks, 364 (309 male and 55 female) patients (59.2 ± 8.4 years, mean SD) were randomized to receive sarpogrelate 200 mg bid, 200 mg tid or placebo for 24 weeks with a follow-up of 8 weeks. The primary objective was the increase of absolute claudication distance (ACD) at the end of treatment (week 24) compared to placebo. Analysis of covariance (ANCOVA) was performed on the log-transformed percentage of baseline ACD: log_e (ACD/baseline). A responder analysis (defined as a 50% improvement in ACD) was also performed. There was a marked training/placebo effect on the ACD which persisted up to 16 weeks. At 24 weeks the primary objective did not reach statistical significance (200 mg bid vs placebo, p = 0.225; 200 mg tid vs placebo, p = 0.580). In the responder analysis, 200 mg bid showed a statistically significant difference vs placebo (p = 0.035). In the exploratory analysis with completers (patients completing all treadmill tests), there was a statistical difference in ACD/baseline change for 200 mg bid (p = 0.035) and in the responder analysis for 200 mg tid (p = 0.044) at 24 weeks compared to placebo. Both treatments showed a carry-over effect for ACD during the 8-week follow-up (weeks 28-32). The treatment was well tolerated and no clinically significant safety concerns were reported. In conclusion, the study results confirm that sarpogrelate is well tolerated and although the primary endpoint failed to reach statistical significance, the responder analysis showed an increased absolute walking distance, which makes a further trial warranted, including a larger population, and possibly also a longer treatment period.

Keywords

intermittent claudication MCI-9042 sarpogrelate walking distance

References

TransAtlantic Inter-Society Consensus (TASC) Working Group . Management of Peripheral Arterial Disease (PAD). J Vasc Surg 2000; 31: S1-S296.

Taylor SM , Kalbaugh CA , Gray BH et al. The LEGS score: a proposed grading system to direct treatment of chronic lower extremity ischemia. Ann Surg 2003; 237: 812-818.

Leng GC , Fowler B , Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000; 2: CD000990.

Clagett GP , Sobel M , Jackson MR , Lip GYH , Tangelder M , Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 609-626.

Nagatomo T , Rashid M , Muntasir HA , Komiyama T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 2004; 104: 59-81.

Rashid M , Manivet P , Nishio H et al. Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sci 2003; 73: 193-207.

Hara H , Osakabe M , Kitajima A , Tamao Y , Kikumoto R. MCI- 9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 1991; 65: 415-420.

Hara H , Osakabe M , Yamada K , Nako K , Tamao Y. Effect of sarpogrelate hydrochloride on contraction of blood vessels. Jpn Pharmacol Ther 1991; 19 (suppl 3): S611-S618.

Hara H , Kitajima A , Tamao Y. Improvement of red blood cell deformability by a new anti-platelet agent, MCI-9042. Clin Hemorheol 1992; 12: 267-277.

10.

Committee for Proprietary Medicinal Products (CPMP) . Note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease. The European Agency for the Evaluation of Medicinal Products, 2002: CPMP/EWP/714/98 rev 1.

11.

Dawson DL , Cutler BS , Hiatt WR et al. A comparison of cilostazol and pentoxifyllin for treating intermittent claudication. Am J Med 2000; 109: 523-530.

12.

Beebe HG , Dawson DL , Cutler BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized multicenter trial. Arch Intern Med 1999; 159: 2041-2050.

13.

Regensteiner JG , Ware JE Jr , McCarthy WJ et al. Effect of cilostazol on treadmill walking, community-based walking ability and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50: 1939-1946.

14.

Katz MF , Farber HW , Dodds-Stitt Z , Cruikshank WW , Beer DJ. Serotonin-stimulated aortic endothelial cells secrete a novel T lymphocyte chemotactic and growth factor. J Leukoc Biol 1994; 55: 567-573.

15.

Prevention of Artherosclerotic Complications With Ketanserin (PACK) Claudication Substudy Investigators . Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. PACK Claudication Substudy. Circulation 1989; 80: 1544-1548.

16.

Verstraete M. The PACK trial; morbidity and mortality effects of ketanserin. Prevention of Atherosclerotic Complications. Vasc Med 1996; 1: 135-140.

17.

Spengel F , Clement D , Boccalon H , Liard F , Brown T , Lehert P. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. Int Angiol 2002; 21: 20-27.

18.

Adhoute G , Andreassian B , Boccalon H et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J Cardiovasc Pharmacol 1990; 16 (suppl 3): S75-S80.

19.

Moody AP , al-Khaffaf HS , Lehert P , Harris PL , Charlesworth D. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994; 23 (suppl 3): S44-S47.

20.

Kieffer E , Bahnini A , Mouren X , Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol 2001; 20: 58-65.

21.

Boccalon H , Lehert P , Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann Cardiol Angeiol (Paris) 2001; 50: 175-182.

22.

Hiatt WR , Hirsch AT , Cooke JP , Olin JW , Brater DC , Creager MA. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vasc Med 2004; 9: 18-25.

23.

Lindgarde F , Jelnes R , Bjorkman H et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989; 80: 1549-1556.

24.

Lievre M , Azoulay S , Lion L , Morand S , Girre JP , Boissel JP. A dose-effect of beraprost sodium in intermittent claudication. J Cardiovasc Pharmacol 1996; 27: 788-793.

25.

Brevetti G , Diehm C , Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999; 34: 1618-1624.

26.

Dawson DL , DeMaioribus CA , Hagino RT et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999; 178: 141-146.

27.

Fujita M , Mizuno K , Ho M et al. Sarpogrelate treatment reduces restenosis after coronary stenting. Am Heart J 2003; 145: e16-e16.

28.

Yamakawa J , Takahashi T , Itoh T et al. A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. Diabetes Care 2003; 26: 2477-2478.